Quince director granted 2,700 stock options

Quince Therapeutics director Christopher J. Senner received a grant of 2,700 stock options for common stock.

Rhea-AI Filing Summary

Quince Therapeutics director Christopher J. Senner received a grant of 2,700 stock options for common stock. These options have an exercise price of $0.947 per share and expire on June 11, 2036. All 2,700 options vest on the one-year anniversary of the grant date, and 2,700 derivative securities are reported as held directly after the transaction.

Insider Trade Summary

Grant/Award: 2,700 shares

Grant/Award 1 txn

Insider Senner Christopher J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	2,700	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 2,700 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.

Key Figures

Stock options granted: 2,700 options Exercise price: $0.947 per share Options expiration: June 11, 2036 +1 more

4 metrics

Stock options granted 2,700 options Director grant of derivative securities

Exercise price $0.947 per share Option strike price for common stock

Options expiration June 11, 2036 Option term end date

Post-transaction derivative holdings 2,700 options Total derivative securities held directly after grant

Key Terms

Director Stock Option, exercise price, vesting

3 terms

Director Stock Option financial

"security_title: "Director Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "0.9470" per share for the option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares subject to this stock option will vest on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quince Therapeutics (QNCX) report for Christopher J. Senner?

Quince Therapeutics reported that director Christopher J. Senner received a grant of 2,700 stock options. These options relate to the company’s common stock and represent a compensation award rather than an open-market purchase or sale of existing shares.

What are the key terms of Christopher J. Senner’s new stock options at Quince Therapeutics (QNCX)?

The grant covers 2,700 stock options with an exercise price of $0.947 per share. The options are exercisable for Quince Therapeutics common stock and expire on June 11, 2036, providing a long-dated equity incentive to the director.

When do Christopher J. Senner’s Quince Therapeutics (QNCX) options vest?

According to the filing footnote, 100% of the 2,700 stock options will vest on the one-year anniversary of the grant date. This means no portion vests earlier, creating a single cliff vesting event after one year.

How many Quince Therapeutics (QNCX) derivative securities does Christopher J. Senner hold after this Form 4 transaction?

Following the grant, the Form 4 reports that Christopher J. Senner holds 2,700 derivative securities. These represent the newly granted stock options, all held directly, with no additional derivative positions shown in the filing’s derivative summary.

Is Christopher J. Senner’s Form 4 transaction a stock purchase or a compensation award at Quince Therapeutics (QNCX)?

The transaction is classified as a grant or award acquisition, not an open-market stock purchase. The options were granted at an exercise price of $0.947 per share, reflecting standard director equity compensation rather than a discretionary market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Senner Christopher J.

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.947	06/11/2026		A		2,700		(1)	06/11/2036	Common Stock	2,700	$0	2,700	D

Explanation of Responses:

1. 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.

	/s/ Brendan Hannah as attorney-in-fact for Christopher J. Senner	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)